Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.

Liang SQ, Bührer ED, Berezowska S, Marti TM, Xu D, Froment L, Yang H, Hall SRR, Vassella E, Yang Z, Kocher GJ, Amrein MA, Riether C, Ochsenbein AF, Schmid RA, Peng RW.

Oncogene. 2019 Jan;38(5):622-636. doi: 10.1038/s41388-018-0479-6. Epub 2018 Aug 31.

PMID:
30171261
2.

Tumor Necrosis Factor-α Initiates miRNA-mRNA Signaling Cascades in Obstruction-Induced Bladder Dysfunction.

Koeck I, Hashemi Gheinani A, Baumgartner U, Vassella E, Bruggmann R, Burkhard FC, Monastyrskaya K.

Am J Pathol. 2018 Aug;188(8):1847-1864. doi: 10.1016/j.ajpath.2018.05.008. Epub 2018 Jun 18.

PMID:
29920227
3.

Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing.

Zhong Q, Wagner U, Kurt H, Molinari F, Cathomas G, Komminoth P, Barman-Aksözen J, Schneider-Yin X, Rey JP, Vassella E, Rogel U, Diebold J, McKee T, Jochum W, Kashofer K, Hofman P, Zischka M, Moch H, Rechsteiner M, Wild PJ.

Pathol Res Pract. 2018 Jul;214(7):957-963. doi: 10.1016/j.prp.2018.05.020. Epub 2018 May 22.

PMID:
29807778
4.

Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.

Wartenberg M, Cibin S, Zlobec I, Vassella E, Eppenberger-Castori S, Terracciano L, Eichmann MD, Worni M, Gloor B, Perren A, Karamitopoulou E.

Clin Cancer Res. 2018 Sep 15;24(18):4444-4454. doi: 10.1158/1078-0432.CCR-17-3401. Epub 2018 Apr 16.

PMID:
29661773
5.

Improved isolation strategies to increase the yield and purity of human urinary exosomes for biomarker discovery.

Gheinani AH, Vögeli M, Baumgartner U, Vassella E, Draeger A, Burkhard FC, Monastyrskaya K.

Sci Rep. 2018 Mar 2;8(1):3945. doi: 10.1038/s41598-018-22142-x.

6.

miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.

Baumgartner U, Berger F, Hashemi Gheinani A, Burgener SS, Monastyrskaya K, Vassella E.

Mol Cancer. 2018 Feb 19;17(1):44. doi: 10.1186/s12943-018-0781-5.

7.

Evolution analysis of heterogeneous non-small cell lung carcinoma by ultra-deep sequencing of the mitochondrial genome.

Amer W, Toth C, Vassella E, Meinrath J, Koitzsch U, Arens A, Huang J, Eischeid H, Adam A, Buettner R, Scheel A, Schaefer SC, Odenthal M.

Sci Rep. 2017 Sep 11;7(1):11069. doi: 10.1038/s41598-017-11345-3.

8.

Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.

Hewer E, Prebil N, Berezowska S, Gutt-Will M, Schucht P, Dettmer MS, Vassella E.

Virchows Arch. 2017 Nov;471(5):641-649. doi: 10.1007/s00428-017-2216-x. Epub 2017 Aug 19.

PMID:
28823044
9.

Low co-expression of epidermal growth factor receptor and its chaperone heat shock protein 90 is associated with worse prognosis in primary glioblastoma, IDH-wild-type.

Sartori E, Langer R, Vassella E, Hewer E, Schucht P, Zlobec I, Berezowska S.

Oncol Rep. 2017 Oct;38(4):2394-2400. doi: 10.3892/or.2017.5863. Epub 2017 Aug 1.

PMID:
28765916
10.

Exosomes and Exosomal MicroRNAs in Prostate Cancer Radiation Therapy.

Malla B, Zaugg K, Vassella E, Aebersold DM, Dal Pra A.

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):982-995. doi: 10.1016/j.ijrobp.2017.03.031. Epub 2017 Mar 27. Review.

PMID:
28721912
11.

MicroRNA dysregulation in the tumor microenvironment influences the phenotype of pancreatic cancer.

Karamitopoulou E, Haemmig S, Baumgartner U, Schlup C, Wartenberg M, Vassella E.

Mod Pathol. 2017 Aug;30(8):1116-1125. doi: 10.1038/modpathol.2017.35. Epub 2017 May 26.

12.

Intestinal differentiated mucinous adenocarcinoma of the endometrium with sporadic MSI high status: a case report.

Trippel M, Imboden S, Papadia A, Mueller MD, Mertineit N, Härmä K, Nicolae A, Vassella E, Rau TT.

Diagn Pathol. 2017 May 12;12(1):39. doi: 10.1186/s13000-017-0629-0.

13.

Hypo-methylation mediates chromosomal instability in pancreatic NET.

Marinoni I, Wiederkeher A, Wiedmer T, Pantasis S, Di Domenico A, Frank R, Vassella E, Schmitt A, Perren A.

Endocr Relat Cancer. 2017 Mar;24(3):137-146. doi: 10.1530/ERC-16-0554. Epub 2017 Jan 23.

14.

PTEN alterations of the stromal cells characterise an aggressive subpopulation of pancreatic cancer with enhanced metastatic potential.

Wartenberg M, Centeno I, Haemmig S, Vassella E, Zlobec I, Galván JA, Neuenschwander M, Schlup C, Gloor B, Lugli A, Perren A, Karamitopoulou E.

Eur J Cancer. 2016 Sep;65:80-90. doi: 10.1016/j.ejca.2016.06.013. Epub 2016 Jul 29.

PMID:
27475963
15.

miR-29b Mediates NF-κB Signaling in KRAS-Induced Non-Small Cell Lung Cancers.

Langsch S, Baumgartner U, Haemmig S, Schlup C, Schäfer SC, Berezowska S, Rieger G, Dorn P, Tschan MP, Vassella E.

Cancer Res. 2016 Jul 15;76(14):4160-9. doi: 10.1158/0008-5472.CAN-15-2580. Epub 2016 May 19. Erratum in: Cancer Res. 2016 Nov 1;76(21):6436.

16.

Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?

Vassella E, Langsch S, Dettmer MS, Schlup C, Neuenschwander M, Frattini M, Gugger M, Schäfer SC.

Oncotarget. 2015 Sep 15;6(27):23905-16.

17.

Combined ATRX/IDH1 immunohistochemistry predicts genotype of oligoastrocytomas.

Hewer E, Vajtai I, Dettmer MS, Berezowska S, Vassella E.

Histopathology. 2016 Jan;68(2):272-8. doi: 10.1111/his.12743. Epub 2015 Jul 27.

PMID:
26016385
18.

Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer.

Tschui J, Vassella E, Bandi N, Baumgartner U, Genitsch V, Rotzer D, Seiler R, Thalmann GN, Fleischmann A.

Virchows Arch. 2015 Jun;466(6):703-10. doi: 10.1007/s00428-015-1729-4. Epub 2015 Mar 26.

19.

Tissue Microarray Technology for Molecular Applications: Investigation of Cross-Contamination between Tissue Samples Obtained from the Same Punching Device.

Vassella E, Galván JA, Zlobec I.

Microarrays (Basel). 2015 Apr 2;4(2):188-95. doi: 10.3390/microarrays4020188.

20.

Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.

Schmitt AM, Pavel M, Rudolph T, Dawson H, Blank A, Komminoth P, Vassella E, Perren A.

Neuroendocrinology. 2014;100(1):35-44. doi: 10.1159/000365514. Epub 2014 Jul 5.

PMID:
25012122
21.

miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas.

Haemmig S, Baumgartner U, Glück A, Zbinden S, Tschan MP, Kappeler A, Mariani L, Vajtai I, Vassella E.

Cell Death Dis. 2014 Jun 5;5:e1279. doi: 10.1038/cddis.2014.245.

22.

Polymorphous oligodendroglioma of Zülch revisited: a genetically heterogeneous group of anaplastic gliomas including tumors of bona fide oligodendroglial differentiation.

Hewer E, Beck J, Murek M, Kappeler A, Vassella E, Vajtai I.

Neuropathology. 2014 Aug;34(4):323-32. doi: 10.1111/neup.12097. Epub 2014 Jan 21.

PMID:
24444336
23.

Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.

Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, Hunger F, Pasquinelli S, Speel EJ, Perren A.

Gastroenterology. 2014 Feb;146(2):453-60.e5. doi: 10.1053/j.gastro.2013.10.020. Epub 2013 Oct 19.

PMID:
24148618
24.

Anaplastic oligodendroglioma arising from the brain stem and featuring 1p/19q co-deletion.

Hewer E, Beck J, Vassella E, Vajtai I.

Neuropathology. 2014 Feb;34(1):32-8. doi: 10.1111/neup.12043. Epub 2013 May 27.

PMID:
23711170
25.

Rosette-forming glioneuronal tumor of the cerebellum in statu nascendi: an incidentally detected diminutive example indicates derivation from the internal granule cell layer.

Thommen F, Hewer E, Schäfer SC, Vassella E, Kappeler A, Vajtai I.

Clin Neuropathol. 2013 Sep-Oct;32(5):370-6. doi: 10.5414/NP300612.

PMID:
23547894
26.

IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival.

Leu S, von Felten S, Frank S, Vassella E, Vajtai I, Taylor E, Schulz M, Hutter G, Hench J, Schucht P, Boulay JL, Mariani L.

Neuro Oncol. 2013 Apr;15(4):469-79. doi: 10.1093/neuonc/nos317. Epub 2013 Feb 13.

27.

Sarcomatous evolution of oligodendroglioma ("oligosarcoma"): confirmatory report of an uncommon pattern of malignant progression in oligodendroglial tumors.

Vajtai I, Vassella E, Hewer E, Kappeler A, Reinert MM.

Pathol Res Pract. 2012 Dec 15;208(12):750-5. doi: 10.1016/j.prp.2012.09.009. Epub 2012 Oct 24.

PMID:
23102810
28.

MAP kinase kinase 1 (MKK1) is essential for transmission of Trypanosoma brucei by Glossina morsitans.

Morand S, Renggli CK, Roditi I, Vassella E.

Mol Biochem Parasitol. 2012 Nov;186(1):73-6. doi: 10.1016/j.molbiopara.2012.09.001. Epub 2012 Sep 8.

PMID:
22985893
29.

Incongruous differential immunoexpression of the MGMT protein in a double adenoma of the pituitary with homogeneous nonmethylated MGMT promoter genotype.

Galli S, Kappeler A, Vassella E, Sahli R, Vajtai I.

Clin Neuropathol. 2012 Mar-Apr;31(2):99-103. No abstract available.

30.
31.

Glycogen-rich pleomorphic xanthoastrocytoma with clear-cell features: confirmatory report of a rare variant with implications for differential diagnosis.

Vajtai I, Stibal A, von Gunten M, Kappeler A, Vassella E, Frank S.

Pathol Res Pract. 2011 Apr 15;207(4):256-61. doi: 10.1016/j.prp.2010.12.008. Epub 2011 Feb 1.

PMID:
21282017
32.

Primer extension based quantitative polymerase chain reaction reveals consistent differences in the methylation status of the MGMT promoter in diffusely infiltrating gliomas (WHO grade II-IV) of adults.

Vassella E, Vajtai I, Bandi N, Arnold M, Kocher V, Mariani L.

J Neurooncol. 2011 Aug;104(1):293-303. doi: 10.1007/s11060-010-0490-4. Epub 2010 Dec 22.

33.

Specific nail alterations in cutaneous T-cell lymphoma: successful treatment with topical mechlorethamine.

Parmentier L, Dürr C, Vassella E, Beltraminelli H, Borradori L, Haneke E.

Arch Dermatol. 2010 Nov;146(11):1287-91. doi: 10.1001/archdermatol.2010.325.

PMID:
21079067
34.

Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.

Ochsenbein AF, Schubert AD, Vassella E, Mariani L.

J Neurooncol. 2011 Jun;103(2):343-51. doi: 10.1007/s11060-010-0395-2. Epub 2010 Sep 21.

35.

miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer.

Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L, Kappeler A, Brunner T, Vassella E.

Cancer Res. 2009 Jul 1;69(13):5553-9. doi: 10.1158/0008-5472.CAN-08-4277. Epub 2009 Jun 23.

36.

Phenotypic associations of Crohn's disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss Cohort.

Schoepfer AM, Schaffer T, Mueller S, Flogerzi B, Vassella E, Seibold-Schmid B, Seibold F.

Inflamm Bowel Dis. 2009 Sep;15(9):1358-67. doi: 10.1002/ibd.20892.

37.

Major surface glycoproteins of insect forms of Trypanosoma brucei are not essential for cyclical transmission by tsetse.

Vassella E, Oberle M, Urwyler S, Renggli CK, Studer E, Hemphill A, Fragoso C, Bütikofer P, Brun R, Roditi I.

PLoS One. 2009;4(2):e4493. doi: 10.1371/journal.pone.0004493. Epub 2009 Feb 18.

38.

Objective response to radiation therapy and long-term survival of patients with WHO grade II astrocytic gliomas with known LOH 1p/19q status.

Fathi AR, Vassella E, Arnold M, Curschmann J, Reinert M, Vajtai I, Weis J, Deiana G, Mariani L.

Strahlenther Onkol. 2007 Sep;183(9):517-22.

39.

A mitogen-activated protein kinase of Trypanosoma brucei confers resistance to temperature stress.

Güttinger A, Schwab C, Morand S, Roditi I, Vassella E.

Mol Biochem Parasitol. 2007 Jun;153(2):203-6. Epub 2007 Feb 16. No abstract available.

PMID:
17368580
40.

Leydig-cell tumour in children: variable clinical presentation, diagnostic features, follow-up and genetic analysis of four cases.

Petkovic V, Salemi S, Vassella E, Karamitopoulou-Diamantis E, Meinhardt UJ, Flück CE, Mullis PE.

Horm Res. 2007;67(2):89-95. Epub 2006 Oct 17.

PMID:
17047343
41.

Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy.

Mariani L, Deiana G, Vassella E, Fathi AR, Murtin C, Arnold M, Vajtai I, Weis J, Siegenthaler P, Schobesberger M, Reinert MM.

J Clin Oncol. 2006 Oct 10;24(29):4758-63. Epub 2006 Sep 11.

PMID:
16966689
42.

A Mitogen-activated protein kinase controls differentiation of bloodstream forms of Trypanosoma brucei.

Domenicali Pfister D, Burkard G, Morand S, Renggli CK, Roditi I, Vassella E.

Eukaryot Cell. 2006 Jul;5(7):1126-35.

43.

Age at diagnosis and loss of heterozygosity on chromosome 1p and 19q in oligodendroglial tumors.

Hergersberg M, Mariani L, Vassella E, Murtin C, Weis J, Moschopulos M, Laeng H, Landolt H, Huber A, Roelcke U.

J Neurooncol. 2006 Nov;80(2):215-7. Epub 2006 May 10.

PMID:
16685464
44.

Expression of procyclin mRNAs during cyclical transmission of Trypanosoma brucei.

Urwyler S, Vassella E, Van Den Abbeele J, Renggli CK, Blundell P, Barry JD, Roditi I.

PLoS Pathog. 2005 Nov;1(3):e22. Epub 2005 Nov 4.

45.

Oligodendroglioma with neurocytic differentiation and characteristic loss of heterozygosity on chromosomes 1p and 19q.

Vajtai I, Arnold M, Vassella E.

Acta Neuropathol. 2005 Nov;110(5):520-2. Epub 2005 Oct 13. No abstract available.

PMID:
16222523
46.

Expression of a major surface protein of Trypanosoma brucei insect forms is controlled by the activity of mitochondrial enzymes.

Vassella E, Probst M, Schneider A, Studer E, Renggli CK, Roditi I.

Mol Biol Cell. 2004 Sep;15(9):3986-93. Epub 2004 Jun 16.

47.

Transformation of monomorphic and pleomorphic Trypanosoma brucei.

McCulloch R, Vassella E, Burton P, Boshart M, Barry JD.

Methods Mol Biol. 2004;262:53-86.

PMID:
14769956
48.

Procyclin null mutants of Trypanosoma brucei express free glycosylphosphatidylinositols on their surface.

Vassella E, Bütikofer P, Engstler M, Jelk J, Roditi I.

Mol Biol Cell. 2003 Apr;14(4):1308-18.

49.

Phosphorylation of GPEET procyclin is not necessary for survival of Trypanosoma brucei procyclic forms in culture and in the tsetse fly midgut.

Bütikofer P, Jelk J, Malherbe T, Vassella E, Acosta-Serrano A, Kunz Renggli C, Brun R, Roditi I.

Mol Biochem Parasitol. 2003 Feb;126(2):287-91. No abstract available.

PMID:
12615329
50.

Stage-specific requirement of a mitogen-activated protein kinase by Trypanosoma brucei.

Müller IB, Domenicali-Pfister D, Roditi I, Vassella E.

Mol Biol Cell. 2002 Nov;13(11):3787-99.

Supplemental Content

Loading ...
Support Center